Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876249 | 0.82 | ANPEP (0.39) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL403860 | 0.81 | ANPEP (0.35) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL404157 | 0.81 | MMP1 (0.36) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL5650452 | 0.79 | ALDH1A1 (0.42) | — | |
| SCHEMBL4876777 | 0.79 | ANPEP (0.37) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL4868337 | 0.72 | ANPEP (0.35) | ANPEPOPRD1OPRM1HDAC3HDAC4 | |
| SCHEMBL2157193 | 0.72 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL4878757 | 0.71 | ITGB1 (0.36) | — | |
| SCHEMBL4873402 | 0.71 | ANPEP (0.36) | ANPEPHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL403598 | 0.70 | ANPEP (0.35) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | ANPEP 744/4885OPRD1 561/4885OPRM1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.